tiprankstipranks
Top Stocks
U.S. Stock Market OverviewTop Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
Top ETFs by AUMSPY ETFQQQ ETF
Stock Comparison
Energy StocksOil StocksBest Value StocksAirline StocksElectric Vehicle StocksMATANA Stocks
New
Bank StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
Global Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsPre-Market BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsTools for Trading PlatformsData for Hedge FundsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Top ETFs by AUM
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
U.S. Markets
Market Movers
Expert Center
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
Top ETFs by AUM
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Energy Stocks
EV Stocks
Crypto News
Dividend Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Pre-Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

ATNF Stock Latest News

180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease
Press Releases180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease
7d ago
ATNF
180 Life announces publication of review on treatments for Dupuytren’s disease
The Fly180 Life announces publication of review on treatments for Dupuytren’s disease
7d ago
ATNF
180 Life Sciences engages Kinexum to support MAA submission for adalimumab
The Fly180 Life Sciences engages Kinexum to support MAA submission for adalimumab
15d ago
ATNF
180 Life Sciences regains compliance with Nasdaq minimum bid price
The Fly180 Life Sciences regains compliance with Nasdaq minimum bid price
27d ago
ATNF
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
Press Releases180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
27d ago
ATNF
180 Life announces publication of review on biological basis of Dupuytren
The Fly180 Life announces publication of review on biological basis of Dupuytren
28d ago
ATNF
180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease
Press Releases180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease
28d ago
ATNF
180 Life Sciences CEO says priorities continue to be clinical programs
The Fly180 Life Sciences CEO says priorities continue to be clinical programs
1M ago
ATNF
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
Press Releases180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
1M ago
ATNF
180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Press Releases180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
1M ago
ATNF
180 Life Sciences announces closing of $6M registered direct offering
The Fly180 Life Sciences announces closing of $6M registered direct offering
1M ago
ATNF
180 Life Sciences announces $6M registered direct offering
The Fly180 Life Sciences announces $6M registered direct offering
1M ago
ATNF
180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Press Releases180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
1M ago
ATNF
180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan
Press Releases180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan
2M ago
ATNF
180 Life Sciences announces 1-for-20 reverse stock split
The Fly180 Life Sciences announces 1-for-20 reverse stock split
2M ago
ATNF
180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture
Press Releases180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture
2M ago
ATNF
180 Life Sciences updates on progress to seek medicines for RIDD
The Fly180 Life Sciences updates on progress to seek medicines for RIDD
2M ago
ATNF
180 Life Sciences to Participate in A.G.P.’s Virtual Biotech Conference to be Held November 30 – December 1, 2022
Press Releases180 Life Sciences to Participate in A.G.P.’s Virtual Biotech Conference to be Held November 30 – December 1, 2022
2M ago
ATNF
CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
Press ReleasesCORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
3M ago
ATNF
180 Life Sciences Issues Letter to Stockholders
Press Releases180 Life Sciences Issues Letter to Stockholders
4M ago
ATNF
180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder
Press Releases180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder
5M ago
ATNF
180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering
Press Releases180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering
7M ago
ATNF
180 Life Sciences: Positive Data From Dupuytren’s Disease Study Could Be a Big Catalyst, Says Analyst
Stock Analysis & Ideas180 Life Sciences: Positive Data From Dupuytren’s Disease Study Could Be a Big Catalyst, Says Analyst
1y ago
ATNF
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.